Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.39 |
| ▸ | DGKA | P23743 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18631797 | 0.98 | NAAA (0.47) | NAAATSHRALDH1A1CES2TP53 | |
| SCHEMBL1722804 | 0.93 | — | — | |
| SCHEMBL5038236 | 0.84 | NAAA (0.42) | NAAATSHRALDH1A1CES2EPHX1 | |
| SCHEMBL27882777 | 0.83 | — | — | |
| SCHEMBL5032705 | 0.82 | NAAA (0.41) | NAAATSHRALDH1A1CES2EPHX1 | |
| SCHEMBL14719802 | 0.81 | NAAA (0.46) | NAAATSHRALDH1A1CES2TP53 | |
| SCHEMBL10871545 | 0.79 | ALDH1A1 (0.33) | NAAATSHRALDH1A1CYP3A4 | |
| SCHEMBL124892 | 0.79 | ALDH1A1 (0.50) | NAAATSHRALDH1A1CES2TP53 | |
| SCHEMBL1526422 | 0.79 | NAAA (0.45) | NAAATSHRALDH1A1CES2EPHX1 | |
| SCHEMBL10615595 | 0.79 | TSHR (0.50) | NAAATSHRCES2EPHX1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4122914-B1 | COMPOUND AND METHOD FOR PREPARATION OF LISDEXAMFETAMINE | SCI PHARMTECH INC (TW) | 2023-08-16 | — | — | EP | claimed |
| US-11608312-B1 | Compound and method for preparation of lisdexamfetamine | SCI PHARMTECH INC. (TW) | 2023-03-21 | — | — | US | claimed |
| US-20230084232-A1 | COMPOUND AND METHOD FOR PREPARATION OF LISDEXAMFETAMINE | SCI PHARMTECH INC. (TW) | 2023-03-16 | — | — | US | claimed |
| EP-4122914-A1 | COMPOUND AND METHOD FOR PREPARATION OF LISDEXAMFETAMINE | SCI Pharmtech Inc. (CN) | 2023-01-25 | — | — | EP | claimed |
| EP-4122914-B1 | COMPOUND AND METHOD FOR PREPARATION OF LISDEXAMFETAMINE | SCI PHARMTECH INC (TW) | 2023-08-16 | — | — | EP | disclosed |
| EP-4215517-A1 | COMPOUND AND METHOD FOR PREPARATION OF LISDEXAMFETAMINE | SCI Pharmtech Inc. (CN) | 2023-07-26 | — | — | EP | disclosed |
| US-11608312-B1 | Compound and method for preparation of lisdexamfetamine | SCI PHARMTECH INC. (TW) | 2023-03-21 | — | — | US | disclosed |
| US-20230084232-A1 | COMPOUND AND METHOD FOR PREPARATION OF LISDEXAMFETAMINE | SCI PHARMTECH INC. (TW) | 2023-03-16 | — | — | US | disclosed |
| EP-4122914-A1 | COMPOUND AND METHOD FOR PREPARATION OF LISDEXAMFETAMINE | SCI Pharmtech Inc. (CN) | 2023-01-25 | — | — | EP | disclosed |
| WO-2013011526-A1 | PROCESS FOR PREPARATION OF LISDEXAMPHETAMINE AND SALTS THEREOF | IND-SWIFT LABORATORIES LIMITED (IN) | 2013-01-24 | — | — | WO | disclosed |
| EP-1656353-B1 | GABANERGIC MODULATORS | HOFFMANN LA ROCHE (CH) | 2010-01-27 | — | — | EP | disclosed |
| US-7365211-B2 | Heterocyclic GABAA subtype selective receptor modulators | ROCHE PALO ALTO LLC (US) | 2008-04-29 | — | — | US | disclosed |
| EP-1730120-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-12-13 | — | — | EP | disclosed |
| EP-1656353-A1 | GABANERGIC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| WO-2005090317-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-09-29 | — | — | WO | disclosed |
| US-20050101614-A1 | For example, 7-(2,4-Dichloro-phenyl)-2-methyl-2H-pyrazolo[4,3-b]pyridine; for treatment of depression, an anxiety disorder, a psychiatric disorder, a learning or cognitive disorder, a sleep disorder, a convulsive or seizure disorder, or pain | ROCHE PALO ALTO LLC | 2005-05-12 | — | — | US | disclosed |
| WO-2005016892-A1 | GABANERGIC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11608312-B1 | Compound and method for preparation of lisdexamfetamine | COMT, CYP2D6, SLC6A3 | NAAA 517/4885TSHR 4238/4885ALDH1A1 1254/4885 |
| US-20050101614-A1 | For example, 7-(2,4-Dichloro-phenyl)-2-methyl-2H-pyrazolo[4,3-b]pyridine; for treatment of depression, an anxiety disorder, a psychiatric disorder, a learning or cognitive disorder, a sleep disorder, a convulsive or seizure disorder, or pain | HTR2C, GABRA2, GABRA4 | NAAA 3164/4885TSHR 1400/4885ALDH1A1 536/4885 |
| US-20230084232-A1 | COMPOUND AND METHOD FOR PREPARATION OF LISDEXAMFETAMINE | COMT, CYP2D6, SLC6A3 | NAAA 517/4885TSHR 4238/4885ALDH1A1 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.